{"success":true,"data":{"pressRelease":{"id":"129777","rtpr_id":"nGNX1pnXd2","ticker":"HTFL","exchange":"NASDAQ","all_tickers":["HTFL"],"title":"Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-08-27T20:01:00.156Z","article_body":"SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow)\n(Nasdaq: HTFL), the leader in AI technology for diagnosing and managing\ncoronary artery disease (CAD), today announced that members of management will\nparticipate in a fireside chat at the upcoming Wells Fargo 21(st) Annual\nHealthcare Conference. The fireside chat, which will include a slideshow\npresentation followed by a question-and-answer session, will take place in\nBoston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.\n\nA live and archived version of the fireside chat will be available on the\nInvestor Relations section of the Heartflow website at\nhttps://ir.heartflow.com.\n\nAbout Heartflow’s Technology and Research\n\nHeartflow’s technology is redefining precision diagnostic testing and\nmanagement for coronary artery disease (CAD) through clinically-proven AI and\nthe world’s largest coronary imaging dataset. Heartflow has been adopted by\nmore than 1,800 institutions globally and continues to strengthen its\ncommercial presence to make this cutting-edge solution more widely available\nto an increasingly diverse patient population. Backed by American College of\nCardiology and American Heart Association (ACC/AHA) guidelines and supported\nby more than 625 peer-reviewed publications, Heartflow has redefined how\nclinicians manage care for over 750,000 patients worldwide.(1) Key benefits\ninclude:\n* Unmatched proprietary data pipeline: Built from the world’s largest\ndatabase of more than 200 million annotated CTA images, Heartflow’s data\nfoundation powers advanced AI models that deliver highly accurate,\nreproducible diagnostic insights across diverse patient populations.\n* Extensive clinical and real-world validation: Heartflow’s AI-driven\nsolutions have been validated through clinical evidence in over 200 studies\nassessing over 365,000 patients. Heartflow is the only AI platform\nprospectively validated against invasive gold standards and demonstrated\nthrough real-world evidence to improve patient outcomes.(2)(,)(3)(,)(4)(,)(5)\nProven in real-world practice with reproducibility and accuracy, Heartflow’s\ncoronary CTA image acceptance rates exceed 97%.\n* Seamless clinical integration via upgraded workflow: Heartflow delivers\nfinal quality-reviewed analyses instantly upon order, enabling clinicians to\nmove from diagnosis to decision without delay.\n* Quality system, global security and patient-data integrity\ncompliance: Heartflow meets or exceeds leading international standards,\nincluding HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.\nAbout Heartflow, Inc.\n\nHeartflow is transforming coronary artery disease from the world’s leading\ncause of death into a condition that can be detected early, diagnosed\naccurately, and managed for life. The Heartflow One\n(https://www.globenewswire.com/Tracker?data=gMZWIkraYGUv3BypDKJu1ffSyTnw2Cke0qrh8xw25oqlLC5HWKvsFTYEYTt5tCva58FW6-uXxgtLLBJeaYFwAlZWzDClm3yrfW8Y0BoToc2516tGEUNf2e4kloGU1RoGFdwT4OUozJet6Jhye_RTeWdVqrXSvgfSdV-V6nacxk-59Uz-KfdJBU8A_Ob_BIgpnruQ4AfJ6IPzkSLnDRlcQHJ1xioDSyLYF5sML_c9l15MHBxkBAwY0Ca-2c3_1p8MfmafLJCpjgYjQDX_0nj91xDOtwSagQC5-npZ1u3X9Hf-koMdCXmIPzb_ptcqFVqAvIf0z5a5wXrRf6cWSc7f4tmyGgplHkBcLNG4fJHkKrN4FTQjdm-3l7jXISUbxEqniDjKh1mum26TlSUtUbouu-eOLSEO-SSGKU363gPtWrbbwdPUCea6HesEm2RkoaWfwy5d9uUm_gwQGPCeQCxXNQWTkX2DHF7g2qlHyO6vrOlGpv7iaHwuWdrWZ8Jb5b4x4Kp_AQQnSZ6XVeNJIr7kplJ2SUMb22CbVl93eLbh9nkILlQxg5ZoP8wyxRPLnvrdZU0vnbStia5iwxyK_DjQDyuRFSyZw1aFYN2bMxjtvyHsja5Qrd-xzWUAx1WTeMlE7YjYoQ8k4CMYisz3iuPPJJ67t8zPr7uD5rWHIRfj0o0luTXcuThVoSSPaYDUHErC-n77OE2B0nRr_Y6BRk3GFJpKdNaSiXH2xD8OnBoND5Q=)\nplatform uses AI to turn coronary CTA images into personalized 3D models of\nthe heart, providing clinically meaningful, actionable insights into plaque\nlocation, volume, and composition and its effect on blood flow — all without\ninvasive procedures. Discover how we’re shaping the future of cardiovascular\ncare at heartflow.com\n(https://www.globenewswire.com/Tracker?data=RdVVuCU3U0EQuUsnqpk4IWEe0thEsRLDjgJK-GktVxFO4wAznc45s9YV_9SrV8z4u5Anzz7sRc2qpl8tv4EiqQ==).\n\nInvestor Contact\nNick Laudico\nnlaudico@heartflow.com\n\nMedia Contact\nElliot Levy\nelevy@heartflow.com\n\n(____________________________________)\n\n(1) Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the\nEvaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454.\n(2) Narula, et al. EHJ CVI 2024.\n(3) Danad, et al. JAMA Cardiol 2017.\n(4) Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death,\nCardiovascular Death and Myocardial Infarction. Presented at AHA 2025.\n(Real-world study with n=7,899 patients, higher TPV results in increased\ncardiovascular death and MI).\n(5) Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions\n2024. (n=900 patients determined a 2.5x increase in cardiovascular events or\ndeaths at 7 years).\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1pnXd2","title":"Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference","author":"Globe Newswire","ticker":"HTFL","created":"2026-08-27T20:01:00.156Z","tickers":["HTFL"],"exchange":"NASDAQ","article_body":"SAN FRANCISCO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow)\n(Nasdaq: HTFL), the leader in AI technology for diagnosing and managing\ncoronary artery disease (CAD), today announced that members of management will\nparticipate in a fireside chat at the upcoming Wells Fargo 21(st) Annual\nHealthcare Conference. The fireside chat, which will include a slideshow\npresentation followed by a question-and-answer session, will take place in\nBoston on Wednesday, September 9, 2026, at 3:45 p.m. ET / 12:45 p.m. PT.\n\nA live and archived version of the fireside chat will be available on the\nInvestor Relations section of the Heartflow website at\nhttps://ir.heartflow.com.\n\nAbout Heartflow’s Technology and Research\n\nHeartflow’s technology is redefining precision diagnostic testing and\nmanagement for coronary artery disease (CAD) through clinically-proven AI and\nthe world’s largest coronary imaging dataset. Heartflow has been adopted by\nmore than 1,800 institutions globally and continues to strengthen its\ncommercial presence to make this cutting-edge solution more widely available\nto an increasingly diverse patient population. Backed by American College of\nCardiology and American Heart Association (ACC/AHA) guidelines and supported\nby more than 625 peer-reviewed publications, Heartflow has redefined how\nclinicians manage care for over 750,000 patients worldwide.(1) Key benefits\ninclude:\n* Unmatched proprietary data pipeline: Built from the world’s largest\ndatabase of more than 200 million annotated CTA images, Heartflow’s data\nfoundation powers advanced AI models that deliver highly accurate,\nreproducible diagnostic insights across diverse patient populations.\n* Extensive clinical and real-world validation: Heartflow’s AI-driven\nsolutions have been validated through clinical evidence in over 200 studies\nassessing over 365,000 patients. Heartflow is the only AI platform\nprospectively validated against invasive gold standards and demonstrated\nthrough real-world evidence to improve patient outcomes.(2)(,)(3)(,)(4)(,)(5)\nProven in real-world practice with reproducibility and accuracy, Heartflow’s\ncoronary CTA image acceptance rates exceed 97%.\n* Seamless clinical integration via upgraded workflow: Heartflow delivers\nfinal quality-reviewed analyses instantly upon order, enabling clinicians to\nmove from diagnosis to decision without delay.\n* Quality system, global security and patient-data integrity\ncompliance: Heartflow meets or exceeds leading international standards,\nincluding HITRUST, SOC 2 Type 2, MDSAP, ISO 13485, and ISO 27001.\nAbout Heartflow, Inc.\n\nHeartflow is transforming coronary artery disease from the world’s leading\ncause of death into a condition that can be detected early, diagnosed\naccurately, and managed for life. The Heartflow One\n(https://www.globenewswire.com/Tracker?data=gMZWIkraYGUv3BypDKJu1ffSyTnw2Cke0qrh8xw25oqlLC5HWKvsFTYEYTt5tCva58FW6-uXxgtLLBJeaYFwAlZWzDClm3yrfW8Y0BoToc2516tGEUNf2e4kloGU1RoGFdwT4OUozJet6Jhye_RTeWdVqrXSvgfSdV-V6nacxk-59Uz-KfdJBU8A_Ob_BIgpnruQ4AfJ6IPzkSLnDRlcQHJ1xioDSyLYF5sML_c9l15MHBxkBAwY0Ca-2c3_1p8MfmafLJCpjgYjQDX_0nj91xDOtwSagQC5-npZ1u3X9Hf-koMdCXmIPzb_ptcqFVqAvIf0z5a5wXrRf6cWSc7f4tmyGgplHkBcLNG4fJHkKrN4FTQjdm-3l7jXISUbxEqniDjKh1mum26TlSUtUbouu-eOLSEO-SSGKU363gPtWrbbwdPUCea6HesEm2RkoaWfwy5d9uUm_gwQGPCeQCxXNQWTkX2DHF7g2qlHyO6vrOlGpv7iaHwuWdrWZ8Jb5b4x4Kp_AQQnSZ6XVeNJIr7kplJ2SUMb22CbVl93eLbh9nkILlQxg5ZoP8wyxRPLnvrdZU0vnbStia5iwxyK_DjQDyuRFSyZw1aFYN2bMxjtvyHsja5Qrd-xzWUAx1WTeMlE7YjYoQ8k4CMYisz3iuPPJJ67t8zPr7uD5rWHIRfj0o0luTXcuThVoSSPaYDUHErC-n77OE2B0nRr_Y6BRk3GFJpKdNaSiXH2xD8OnBoND5Q=)\nplatform uses AI to turn coronary CTA images into personalized 3D models of\nthe heart, providing clinically meaningful, actionable insights into plaque\nlocation, volume, and composition and its effect on blood flow — all without\ninvasive procedures. Discover how we’re shaping the future of cardiovascular\ncare at heartflow.com\n(https://www.globenewswire.com/Tracker?data=RdVVuCU3U0EQuUsnqpk4IWEe0thEsRLDjgJK-GktVxFO4wAznc45s9YV_9SrV8z4u5Anzz7sRc2qpl8tv4EiqQ==).\n\nInvestor Contact\nNick Laudico\nnlaudico@heartflow.com\n\nMedia Contact\nElliot Levy\nelevy@heartflow.com\n\n(____________________________________)\n\n(1) Gulati M, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCAI Guideline for the\nEvaluation and Diagnosis of Chest Pain. Circulation 2021; 144:e368–e454.\n(2) Narula, et al. EHJ CVI 2024.\n(3) Danad, et al. JAMA Cardiol 2017.\n(4) Fairbairn et al. Coronary CT Angiography Plaque as a Predictor of Death,\nCardiovascular Death and Myocardial Infarction. Presented at AHA 2025.\n(Real-world study with n=7,899 patients, higher TPV results in increased\ncardiovascular death and MI).\n(5) Madsen KT, et al. ADVANCE-DK 7-year. Presented at TCT Scientific Sessions\n2024. (n=900 patients determined a 2.5x increase in cardiovascular events or\ndeaths at 7 years).\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c6be111e-2f8e-4ac8-8fa8-310dbcbd6e15)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-27T20:01:00.212565153Z","server_sent_at_ms":1787860860212},"received_at":"2026-08-27T20:01:00.443Z","source_url":null},"analysis":{"id":"118691","press_release_id":"129777","analysis_json":{"industry":{"label":"Health Care Technology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Heartflow announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026.\n\nThe session, featuring a slideshow presentation and Q&A, will be webcast live and archived on the company's investor relations website.\n\nHeartflow provides AI-driven technology for diagnosing and managing coronary artery disease, currently utilized by more than 1,800 institutions globally.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance announcement."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Nick Laudico","role":"Investor Contact"},{"name":"Elliot Levy","role":"Media Contact"}],"products":["Heartflow One"],"companies":[{"name":"Heartflow, Inc.","ticker":"HTFL"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"American College of Cardiology","relationship":"guideline body"},{"name":"American Heart Association","relationship":"guideline body"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of participation in an investor conference with no new financial data or operational disclosures."},"tickerRelevance":{"others":[],"primary":"HTFL"},"globalImportance":10,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"conference_announcement","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Heartflow announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on September 9, 2026.\n\nThe session, featuring a slideshow presentation and Q&A, will be webcast live and archived on the company's investor relations website.\n\nHeartflow provides AI-driven technology for diagnosing and managing coronary artery disease, currently utilized by more than 1,800 institutions globally.","key_figures":null,"named_entities":{"people":[{"name":"Nick Laudico","role":"Investor Contact"},{"name":"Elliot Levy","role":"Media Contact"}],"products":["Heartflow One"],"companies":[{"name":"Heartflow, Inc.","ticker":"HTFL"},{"name":"Wells Fargo","relationship":"conference organizer"},{"name":"American College of Cardiology","relationship":"guideline body"},{"name":"American Heart Association","relationship":"guideline body"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T20:03:43.795Z","global_importance":10,"audience_relevance":5,"importance_components":{"tickerTier":"mid-cap","eventGravity":"conference_announcement","issuerAuthored":true}},"durationMs":67884,"modelName":"glm-4.7"}}